A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

被引：5

作者：

Ong, Faustine ^{[1
]}

Short, Nicholas ^{[2
]}

Daver, Naval ^{[2
]}

Kadia, Tapan M. ^{[2
]}

DiNardo, Courtney D. ^{[2
]}

Yilmaz, Musa ^{[2
]}

Alvarado, Yesid ^{[2
]}

Vaughan, Kenneth ^{[2
]}

Pierce, Sherry A. ^{[2
]}

Kantarjian, Hagop ^{[3
]}

Garcia-Manero, Guillermo ^{[2
]}

Ravandi, Farhad ^{[4
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, CA USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA

[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-159110

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

615

引用

页码：9029 / 9031

页数：3

共 50 条

[11] Phase II study of cladribine, idarubicin, cytarabine (CLIA) plus gilteritinib in patients (pts) with FLT3 mutated acute myeloid leukemia (AML).
Abuasab, Tareq
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
Bravo, Guillermo Montalban
Valero, Yesid Alvarado
Daver, Naval Guastad
Yilmaz, Musa
Pemmaraju, Naveen
Chien, Kelly Sharon
Kornblau, Steven Mitchell
Burger, Jan Andreas
Jain, Nitin
Islam, Rabiul
Dinardo, Courtney Denton
Borthakur, Gautam
Jabbour, Elias
Ravandi, Farhad
Kadia, Tapan M.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[12] a Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval
Assi, Rita
Garcia-Manero, Guillermo
Ravandi, Farhad
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Kadia, Tapan
Ning, Jing
Gonzalez, Graciela Nogueras
Pierce, Sherry
Kelly, Mary
Zhang, Weiguo
Gombos, Dan
Kornblau, Steven
Konopleva, Marina
Cortes, Jorge E.
Kantarjian, Hagop M.
Andreeff, Michael
BLOOD, 2017, 130
[13] Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
Perl, A. E.
Martinelli, G.
Cortes, J. E.
Neubauer, A.
Berman, E.
Paolini, S.
Montesinos, P.
Baer, M. R.
Larson, R. A.
Ustun, C.
Fabbiano, F.
Erba, H. P.
Di Stasi, A.
Stuart, R.
Olin, R.
Kasner, M.
Ciceri, F.
Chou, W-C
Podoltsev, N.
Recher, C.
Yokoyama, H.
Hosono, N.
Yoon, S-S
Lee, J-H
Pardee, T.
Fathi, A. T.
Liu, C.
Hasabou, N.
Liu, X.
Bahceci, E.
Levis, M. J.
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (18): : 1728 - 1740
[14] Gilteritinib-Based Combination Therapy in Adult Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia
Chen, Nianci
Pan, Jiajia
Zhou, Yile
Mao, Liping
Lou, Yinjun
Qian, Jiejing
Xu, Gaixiang
Wei, Juying
Zhou, De
Shou, Lihong
Li, Huang
Yan, Minchao
Zeng, Hui
Fan, Cuihua
Wu, Gongqiang
Feng, Weiying
Tong, Hongyan
Jin, Jie
Wang, Huafeng
BLOOD, 2023, 142
[15] The Frida Study: An Option for Mutated FLT3 Relapsed/Refractory Acute Myeloid Leukemia Patients with a Novel Iadademstat and Gilteritinib Combination Therapy
Fathi, Amir T.
Arevalo, Mabel
Gutierrez, Sonia
Molero, Antonieta
Sacilotto, Natalia
Limon, Ana
Faller, Douglas, V
BLOOD, 2022, 140 : 11755 - 11756
[16] Phase II Randomized Trial of Gilteritinib Vs Midostaurin in Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AML)
Luger, Selina M.
Sun, Zhuoxin
Loghavi, Sanam
Lazarus, Hillard M.
Rowe, Jacob M.
Tallman, Martin S.
Pratz, Keith W.
Litzow, Mark
BLOOD, 2019, 134
[17] Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia
McMahon, Christine M.
Canaani, Jonathan
Rea, Bryan
Sargent, Rachel Lynn
Morrissette, Jennifer J. D.
Lieberman, David B.
Watt, Christopher
Schwartz, Gregory W.
Faryabi, Robert B.
Ferng, Timothy T.
Shah, Neil P.
Smith, Catherine C.
Carroll, Martin
Perl, Alexander E.
BLOOD, 2017, 130
[18] Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy
Abuasab, Tareq
Garcia-Manero, Guillermo
Short, Nicholas
Alvarado, Yesid
Issa, Ghayas C.
Islam, Rubiul
Maiti, Abhishek
Yilmaz, Musa
Jain, Nitin
Masarova, Lucia
Kornblau, Steven M.
Jabbour, Elias
Pemmaraju, Naveen
Montalban-Bravo, Guillermo
Pierce, Sherry A.
DiNardo, Courtney D.
Kadia, Tapan M.
Daver, Naval
Konopleva, Marina
Kantarjian, Hagop
Ravandi, Farhad
BLOOD, 2022, 140 : 3324 - 3326
[19] Final Results of Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
Daver, Naval G.
Assi, Rita
Kantarjian, Hagop M.
Cortes, Jorge E.
Ravandi, Farhad
Konopleva, Marina Y.
Kadia, Tapan M.
Borthakur, Gautam
Jabbour, Elias J.
DiNardo, Courtney D.
Velasquez, Michelle
Kelly, Mary
Ning, Jing
Gonzalez, Graciela M. Nogueras
Pierce, Sherry A.
Gombos, Dan
Estrov, Zeev E.
Kornblau, Steven M.
Zhang, Weiguo
Andreeff, Michael
BLOOD, 2018, 132
[20] Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia
Daver, Naval
Perl, Alexander E.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James
Smith, Catherine C.
Schiller, Gary
Bradley, Terrence
Tiu, Ramon, V
Naqvi, Kiran
Dail, Monique
Brackman, Deanna
Siddani, Satya
Wang, Jing
Chyla, Brenda
Lee, Paul
Altman, Jessica K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (35) : 4048 - +

← 1 2 3 4 5 →